Novo Nordisk, Denmark’s — and by most measures Europe’s — most consequential pharmaceutical company, reported second-quarter results on 4 August that beat expectations and lifted its full-year guidance. Adjusted operating profit came in at DKK 33.4 billion, up 11% at constant exchange rates, on net sales of DKK 78.5 billion, up 3% at constant rates — a quarter driven by GLP-1 volume growth and favourable US rebate adjustments. For the corridor this publication covers, the print matters twice over: it is the health check on the Nordic region’s largest company, and it is a demand signal for the Portuguese plants that sit quietly inside the obesity-drug supply chain.
The Copenhagen-listed group raised its 2026 outlook, now guiding adjusted sales and operating-profit growth of minus 6% to zero at constant exchange rates, an improvement on the previous range of minus 12% to minus 4%. The upgrade rests on stronger-than-expected GLP-1 product sales. Even so, the market’s verdict was mixed: the shares fell on the day, with investors noting that even the improved guidance still implies a year of contraction for a company that until recently compounded at double digits, amid intensifying competition in the obesity category.
The pill is the story
The operational headline of the quarter is the oral formulation. The Wegovy pill exceeded 265,000 total weekly US prescriptions in the week ending 17 July, and the wider Wegovy portfolio has passed five million prescriptions since launch, with the company pointing to encouraging early uptake in markets outside the United States, launches in the UK and UAE, and the rollout of the higher-dose Wegovy HD (7.2 mg). The strategic logic is straightforward: tablets are easier to ship, store and prescribe than injection pens — and they are far more manufacturing-intensive in exactly the disciplines where Portugal’s pharmaceutical cluster earns its living.
The Portuguese link in a Danish machine
As NorthSouth HQ detailed earlier this year, Hovione — the Loures-headquartered contract development and manufacturing organisation founded in 1959 — is one of the world’s leading specialists in spray drying and particle engineering, the technologies that turn fragile peptide molecules into stable, absorbable tablets. That expertise places the Portuguese company inside the supply chain of oral semaglutide, the molecule behind Novo Nordisk’s tablet franchise. Hovione runs FDA-inspected plants in Portugal, Ireland, the United States and China, and has spent decades — and hundreds of millions of euros — building spray-drying and continuous-manufacturing capacity, much of it near Lisbon.
Every quarter in which the oral obesity franchise outgrows the injectable one — and this was such a quarter — tilts value toward that kind of high-barrier formulation work. Portugal’s broader pharmaceutical-chemical cluster, from the family-owned drugmaker Bial to a widening ring of specialty producers, sells into European and Nordic customers on the same logic: complex chemistry, reliable regulatory track record, euro-zone cost base. The GLP-1 boom is the most visible current expression of a corridor lane that predates Ozempic by decades.
Reading the quarter from Lisbon
The bear case on Novo Nordisk — compounding competition from Eli Lilly, US pricing pressure, the end of the land-grab phase — is real, and the share-price reaction reflected it. But for the industrial ecosystem beneath the brand, the relevant numbers point the other way: volumes are growing, the oral franchise is scaling fast, and the company just told the market that demand is coming in ahead of its own plan. Manufacturing partners get paid on volume, not on multiple compression in Copenhagen.
What to watch next: Novo Nordisk’s capacity announcements through the autumn, and any that name Iberian sites or partners; Hovione’s own expansion cadence in Loures and Sines; competitive dynamics as oral obesity rivals approach the market; and the Q3 print in early November, where the durability of the raised guidance gets its first test.